Allostery Investments LP purchased a new stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 850,684 shares of the company's stock, valued at approximately $2,254,000. Aerovate Therapeutics makes up 2.3% of Allostery Investments LP's holdings, making the stock its 14th biggest holding. Allostery Investments LP owned 2.95% of Aerovate Therapeutics as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the business. ADAR1 Capital Management LLC raised its stake in Aerovate Therapeutics by 720.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock valued at $2,459,000 after purchasing an additional 814,941 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Aerovate Therapeutics in the 4th quarter valued at about $1,280,000. Affinity Asset Advisors LLC grew its stake in Aerovate Therapeutics by 33.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $2,120,000 after buying an additional 200,000 shares during the period. Deltec Asset Management LLC purchased a new position in shares of Aerovate Therapeutics in the 4th quarter valued at $514,000. Finally, FNY Investment Advisers LLC purchased a new stake in Aerovate Therapeutics during the 4th quarter worth $198,000.
Aerovate Therapeutics Price Performance
NASDAQ AVTE traded down $1.41 on Wednesday, reaching $10.09. The company had a trading volume of 424,316 shares, compared to its average volume of 17,925. The firm has a market capitalization of $292.46 million, a PE ratio of -3.37 and a beta of 0.95. The firm has a 50-day moving average of $79.90 and a 200-day moving average of $85.85. Aerovate Therapeutics, Inc. has a 1 year low of $43.75 and a 1 year high of $884.98.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, sell-side analysts expect that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.
Aerovate Therapeutics Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, April 28th. Shareholders of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date of this dividend was Tuesday, April 29th.
About Aerovate Therapeutics
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
